When was CytoDyn founded?

CytoDyn was founded in 2002 and raised its 1st funding round 7 years after it was founded.

Where is CytoDyn located?

CytoDyn is headquartered in Vancouver, United States. It is registered at Vancouver, Washington.

How many employees does CytoDyn have?

As of Jul 31, 2026, the latest employee count at CytoDyn is 23.

Is CytoDyn a funded company?

CytoDyn is a funded company, having raised an undisclosed amount across 23 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Oct 20, 2009.

When was the latest funding round of CytoDyn?

CytoDyn's latest funding was a $***** Post IPO round on Mar 05, 2026, with participation from 0 investor.

What is the annual revenue of CytoDyn?

Annual revenue of CytoDyn is less than $1M as on May 31, 2022

Where does CytoDyn rank among its competitors?

CytoDyn ranks 572nd amongst 3753 active competitors, of which 1265 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of CytoDyn?

CytoDyn's top competitors include Jazz Pharmaceuticals, BeiGene and argenx. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

CytoDyn - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection. It offers lead candidate, PRO 140,for HIV with demonstrated antiviral activity in men. PRO 140 blocks the HIV co-receptor CCR5 on T-cells that prevent viral entry.

Website: www.cytodyn.com/
Social
Registered Address: Vancouver, Washington

Key Metrics

Founded Year

2002

Location

Vancouver, United States

Stage

Public

Latest Funding Round

Post IPO, Mar 05, 2026, $*****

Investors

Centrecourt Asset Management & 2 more

Ranked

572^nd among 3753 active competitors

Annual Revenue

$0 - $1M as on May 31, 2022

Employee Count

23 as on Jul 31, 2026

Investment & Acquisitions

ProstaGene

Similar Companies

Jazz Pharmaceuticals & 3575 more

Exit Details

Public

View CytoDyn's full profile

CytoDyn is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CYTODYN INC CIN: 753056237 , United States, Active	Dec 31, 1999	-	11 (As on Dec 31, 2024)	-
Cytodyn Inc. CIN: 1175680 , United States, Active	Aug 26, 2018	$0 - $1M (As on May 31, 2022)	-	-

CytoDyn got listed on Nov 25, 2005.

Click here to take a look at CytoDyn's IPO in detail

CytoDyn has raised funding over 23 rounds. Its first funding round was on Oct 20, 2009. CytoDyn has 3 institutional investors.

Here is the list of recent funding rounds of CytoDyn:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 05, 2026	8200387	Post IPO	3147779	2978316	4619247	7754560
Jan 30, 2026	6889438	Post IPO	2323210	5693833	1837917	2186468
Apr 25, 2022	9373972	Post IPO	4485205	2642458	7850467	8843052

Access funding benchmarks and valuations. Sign up today!

View details of CytoDyn's funding rounds and investors

CytoDyn's employee count trend

CytoDyn has 23 employees as of Jul 26. Here is CytoDyn's employee count trend over the years:

Uncover CytoDyn's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CytoDyn include Jazz Pharmaceuticals, BeiGene and argenx. Here is the list of Top 10 competitors of CytoDyn, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	CareDx 1998, Brisbane (United States), Public	Developer of medical solutions for transplant patients	$138M	Intel, Integral Capital Partners & 24 others	73/100
7th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
8th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
9th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
10th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
572nd	CytoDyn 2002, Vancouver (United States), Public	Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection	-	Centrecourt Asset Management, Cool Blue Capital ... & 1 others	52/100